Bot Detector
Download FREE Sample Issue or Article
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Evaluation of Percutaneous Absorption Performance for Human Female Sexual Steroids into Pentravan Cream

Author(s):  Polonini Hudson C, Brandão Marcos Antônio F, Ferreira Anderson O, Ramos Cristiano, Raposo Nádia R B

Issue:  Jul/Aug 2014 - Volume 18, Number 4
View All Articles in Issue

Abstract:  There is a lack of studies on Pentravan cream, a widespread transdermal vehicle which is used by compounding pharmacies. The purpose of this study was to evaluate this transdermal vehicle. The permeation performance for progesterone, estradiol, and estriol in formulations containing each of those drugs separately, as well as an association of estradiol + estriol (Biest), was evaluated regarding their compounding process and their potential biological application. An excised female human skin model was used to predict the permeation and the retention of the active compounds in every skin layer in lieu of conventional tape stripping. Progesterone was the drug with the highest permeation (37.02 mcg cm–2 at the end of the experiment). Estradiol and estriol in Biest had permeations approximately 4-fold lower (9.44 mcg cm–2 for estradiol-Biest and 14.02 mcg cm–2 for estriol-Biest), and the profiles of estradiol in Eemuls and in Biest were almost the same (9.46 mcg cm–2 for Eemuls). All permeations followed pseudofirst order kinetics. For progesterone, using the percentage of permeation by dose, one can infer that a patient using the 1-g emulsion dose released by the pump containing 50 mg of progesterone will have 38.4 mg of progesterone liberated into his bloodstream, gradually and continuously for 48 hours. The results indicate that the vehicle was able to provide percutaneous absorption rates compatible with and higher than clinical treatment needs. Using the same rationale, the Eemuls would deliver practically the entire amount of estradiol load per dose (1.0 mg), approximately 0.5 mg of estradiol per day. As for the Biest, the dosing used would deliver almost 0.5 mg estradiol/day and 2.0 mg estriol/ day. Thus, according to the results, human female sexual hormones incorporated in the oil-in-water vanishing cream base and applied topically are expected to exert their biological activities systemically with good efficacy due to their satisfactory permeation through human skin. However, one must take into account that a high quantity of drug was delivered. Thus, to avoid patient overdose, care has to be taken regarding the quantity of emulsion used.

Related Keywords: Hudson C. Polonini, PhD, Marcos Antônio F. Brandão, PhD, Anderson O. Ferreira, MSc, Cristiano Ramos, MD, Nádia R. B. Raposo, PhD, sex steroids, hormone replacement, women, topical preparations, transdermal absorption, percutaneous absorption, progesterone, estradiol, estriol, estrogen, Pentravan cream, oil-in-water vanishing cream, semisolid formulations, transdermal vehicle, human skin permeation, drug retention, semisolid dosage forms, dermal permeability, patient compliance, patient adherence, airless plunger pump dosage control


Printer-Friendly Version

Download in electronic PDF format for $55

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Evaluation of Percutaneous Absorption Performance for Human Female Sexual Steroids into Pentravan Cream Polonini Hudson C, Brandão Marcos Antônio F, Ferreira Anderson O, Ramos Cristiano, Raposo Nádia R B Jul/Aug 2014 332-340 Buy
Veterinary Transdermal Medications: A to Z Davidson Gigi S Mar/Apr 2003 106-113 Buy
Transdermal Delivery of Metformin Hydrochloride from a Semisolid Vehicle Polonini Hudson, Lopes Cândido Paulo José, Andrade Junquiera Laura, Loures Sharlene, Raposo Nádia RB, Fernandes Brandão Marcos Antônio, de Oliveira Ferreira Anderson Jan/Feb 2019 65-69 Buy
Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy Laque Larissa C, Raposo Nádia RB, Fernandes Brandão Marcos Antônio, de Oliveira Ferreira Anderson, Polonini Hudson C Jan/Feb 2019 77-81 Buy
Orodispersible Films for Compounding Pharmacies Ferreira Anderson O, Brandão Marcos Antônio F, Raposo Francisco José, Polonini Hudson C, Raposo Nádia Rezende Barbosa Nov/Dec 2017 454-461 Buy
Compatibility of Estradiol, Estriol, Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base Polonini Hudson C, Dijkers Eli, Ferreira Anderson O, Zander Clark, Taylor Sarah Jul/Aug 2021 336-343 Buy
Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan for Transdermal and Transmucosal Application Polonini Hudson, de Oliveira Ferreira Anderson, Dijkers Eli Sep/Oct 2021 422-426 Buy
Compounded Orodispersible Films with Natural Ingredients for Halitosis: A Clinical Experience Apolinário Régis De Souza, Chaves Maria Das Graças Afonso Miranda, Gonçalves Hanny Reis Mockdeci, Martins Isadora Conde Ferreria, De Paula Renée Mazilão, Granato Ana Paula Alves, Polonini Hudson Caetano, Brandão Marcos Antônio Fernandes, Ferreira Anderson De Oliveira, Raposo Nádia Rezende Barbosa Nov/Dec 2018 512-515 Buy
Stability of Allopurinol, Amitriptyline Hydrochloride, Carbamazepine, Domperidone, Isoniazid, Ketoconazole, Lisinopril, Naproxen, Paracetamol (Acetaminophen), and Sertraline Hydrochloride in SyrSpend SF PH4 Oral Suspensions Polonini Hudson C, Loures Sharlene, de Araujo Edson Peter, Brandão Marcos Antônio F, Ferreira Anderson O Sep/Oct 2016 426-434 Buy
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4 Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira Nov/Dec 2018 516-526 Buy